Chapter 4 — Further Reading

Tier 1 — Verified canonical

Pharmacokinetics as a discipline. Goodman & Gilman's The Pharmacological Basis of Therapeutics covers absorption, distribution, metabolism, excretion, half-life, and bioavailability thoroughly and is this book's named reference. Rowland and Tozer's Clinical Pharmacokinetics and Pharmacodynamics is the standard specialist text if you want the quantitative treatment.

Drug labels as primary sources. This is the highest-value recommendation in this chapter's list. DailyMed (U.S. National Library of Medicine) carries the complete approved labeling for every drug marketed in the United States, free and searchable. Every label contains a Clinical Pharmacology section giving absorption, distribution, metabolism, elimination, and half-life, and a Dosage and Administration section that is pharmacokinetics made operational.

Read three, side by side, and you will learn more about §4.3 than from any textbook:

• Semaglutide injection (Ozempic or Wegovy) — note how few administration constraints there are
• Semaglutide tablets (Rybelsus) — note the fasting window, the water volume, the waiting period
• Exenatide (Byetta) — note the twice-daily schedule and the meal timing

The contrast between the first two is Chapter 4's entire argument, written by a regulator.

Exenatide. Approved by the FDA in 2005 as the first GLP-1 receptor agonist. Derived from exendin-4, a peptide identified in the venom of the Gila monster (Heloderma suspectum). Approval records public via Drugs@FDA.

Inhaled insulin. Exubera was approved in 2006 and withdrawn from the market in 2007. Afrezza was approved in 2014, carries a boxed warning regarding bronchospasm, is contraindicated in asthma and COPD, and requires lung function assessment. Both approval histories are public via Drugs@FDA, and Afrezza's current label is on DailyMed.

Regulatory guidance on immunogenicity. The FDA and EMA both publish guidance documents on the assessment of immunogenicity for therapeutic proteins and peptides. These are free, dry, and unusually informative about what industry is actually required to test for — including aggregation control, which is §4.7's link to Chapter 19.

Tier 2 — Attributed, specifics unverified

On half-lives. Values given in this chapter are approximate and drawn from standard references. Half-life varies with route, dose, renal function, and individual factors; the figures are stated as approximations deliberately. Where a precise value matters clinically, the label is the source.

On the renal filtration cutoff. Commonly given as approximately 5,000 Da for free filtration, with the cutoff softening across a range up to tens of thousands of daltons depending on molecular shape and charge. Exact figures vary by source and by how "freely filtered" is defined.

On exendin-4's sequence similarity to human GLP-1. Commonly reported as roughly 50%. The therapeutically important point is not the percentage but that the DPP-4 recognition site is absent — which is a structural fact rather than a statistical one.

On the causes of Exubera's commercial failure. Device size, dosing units, monitoring requirements, smoking exclusion, and pricing are all widely cited. The relative weight of each is a matter of commercial analysis rather than established fact, and this book presents them as contributing factors rather than a ranked diagnosis.

On insulin therapy delay. That reluctance to begin injectable insulin contributes to delayed initiation and worse glycemic control is well described in the diabetes care literature, sometimes termed "psychological insulin resistance." Magnitudes vary by population and health system.

On GLP-1 manufacturing constraints during shortage. That aseptic fill-finish capacity and injector pen assembly, rather than peptide synthesis, were the binding constraints is widely reported and consistent with public statements by manufacturers. Specific capacity figures are not stated here.

Tier 3 — Illustrative and constructed

• All ASCII diagrams in this chapter — the oral gauntlet, the two exits, the half-life and dosing table, the semaglutide modification map, the cost breakdown, and the delivery filter — are schematic teaching devices. The cost breakdown in §4.8 is explicitly labeled as an illustrative structure and does not represent any specific drug's cost accounting.
• The worked Field 4 dossier entries for native GLP-1 and semaglutide are demonstrations constructed for this book from publicly available information.
• The five-question delivery filter in §4.9 is this book's own construction.

If you only read one thing

Open the Rybelsus label on DailyMed and read Section 2, Dosage and Administration.

It is under a page. It specifies that the tablet be taken on an empty stomach, with no more than a specified small volume of water, with a waiting period before eating, drinking, or taking other oral medications, and swallowed whole.

Then open the Ozempic label and read the same section. Once weekly, any day of the week, with or without food.

Same molecule. Same company. One page of constraints versus one sentence. Everything in Chapter 4 is the explanation for that difference, and seeing it in the regulator's own words makes it stick in a way no diagram does.

Looking ahead

Chapter 5 is the book's most important chapter and it requires no preparation — it starts from nothing. If you want to arrive warmed up, the single most useful thing is to find one clinical trial abstract for any drug you care about (PubMed is free; ClinicalTrials.gov is free and lists trial designs including ones that never published) and read it without trying to understand it. Then read it again after Chapter 5. The difference between those two readings is what the chapter is for.